Related Experiment Videos
Calcium channel blockers in heart failure
1Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033, USA.
Cardiology
|May 7, 1998
Summary
Calcium channel blockers (CCBs) show mixed results in chronic heart failure (CHF). While some are detrimental, amlodipine shows promise for reducing mortality in specific CHF patient groups.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Calcium channel blockers (CCBs) have been extensively studied for chronic heart failure (CHF).
- First-generation CCBs may have detrimental effects in CHF patients with reduced left ventricular systolic function.
- Second-generation CCBs have shown vasodilatory effects but not improved exercise capacity, morbidity, or mortality.
Purpose of the Study:
- To evaluate the safety and efficacy of CCBs in patients with chronic heart failure (CHF).
- To analyze the impact of various CCBs on exercise capacity, morbidity, and mortality in CHF patients.
Main Methods:
- Review of available studies on CCBs in chronic heart failure.
- Analysis of data from clinical trials such as V-HeFT III, PRAISE, PRAISE II, and MACH-1.
Main Results:
- Some CCBs (nicardipine, nisoldipine) show detrimental effects in moderate-to-severe heart failure.
- Felodipine did not show unfavorable effects on exercise tolerance in V-HeFT III, but mortality conclusions were limited.
- The PRAISE study indicated amlodipine is safe in heart failure due to coronary artery disease and reduces mortality in nonischemic cardiomyopathy.
Conclusions:
- CCBs have a complex role in CHF treatment, with varying safety and efficacy profiles.
- Amlodipine shows potential therapeutic benefit as an add-on therapy for specific CHF populations.
- Further research, including PRAISE II and MACH-1, is needed to clarify the role of CCBs in chronic heart failure.